IMR Press / FBL / Volume 28 / Issue 5 / DOI: 10.31083/j.fbl2805103
Open Access Review
Sodium-Glucose Co-Transporters Family: Current Evidence, Clinical Applications and Perspectives
Show Less
1 Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli'', 80138 Naples, Italy
2 Internal Medicine and Hepatology Unit, Ospedale Evangelico Betania, 80147 Naples, Italy
3 Department of Translational Medical Sciences, University of Campania ‘Luigi Vanvitelli', 80138 Naples, Italy
*Correspondence: (Riccardo Nevola)
These authors contributed equally.
Front. Biosci. (Landmark Ed) 2023, 28(5), 103;
Submitted: 11 November 2022 | Revised: 7 April 2023 | Accepted: 28 April 2023 | Published: 25 May 2023
(This article belongs to the Special Issue An Update on Sodium Glucose Co-Transporters)
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Sodium-glucose co-transporters (SGLTs) family members are involved in several vital biological functions. Except for SGLT3, they are involved in the mechanisms of active transport of sodium and glucose and several micromolecules. The discovery of functions and mechanisms of SGLT1 inhibition and, in particular, of SGLT2 has radically changed the natural history of some pathologies. SGLT2 inhibitors have revolutionized the therapeutic approach not only of type 2 diabetes mellitus but also of heart failure and chronic kidney failure. Considering the role played by the other SGLTs and the functions still unknown to date, clinical implications of the inhibition of SGLT2 could represent the prelude for a wider modulation of these cotransporters. A better understanding of the role and function of SGLTs could represent a revolution in the therapeutic approach in the hepatological, metabolic, neurological and oncological fields. The purpose of this review is to illustrate the knowledge currently available on SGLTs, its clinical implications and future perspectives.

Sodium Glucose Transporters
SGLT2 inhibitors
heart failure
chronic kidney failure
diabetes mellitus
Fig. 1.
Back to top